Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T65116 Target Info
Target Name Ecto-5'-nucleotidase (CD73)
Synonyms NT5; CD73 antigen; 5'-nucleotidase; 5'-NT
Target Type Clinical trial Target
Gene Name NT5E
Biochemical Class Phosphoric monoester hydrolase
UniProt ID
5NTD_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
World Intellectual Property Organization (WIPO)
Patent ID WO2016131950
Title Cd73 Blockade.
Abstract This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5' nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.
Applicant(s) Innate Pharma
Patent ID WO2016055609
Title Cd73 Blockade.
Abstract This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5' nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.
Applicant(s) Innate Pharma
Patent ID WO2016134091
Title Method for Improving Learning.
Abstract The invention is directed to a method for improving learning and/or memory (e.g., auditory, visual, somatosensory or motor) in adults and children of an age which is beyond the early critical period for learning, said method comprising inhibiting (i) ecto-5'-nucleotidase (Nt5e, aka CD73) or (ii) A1 adenosine receptor (A1R, aka Adora1) expression or function in the brain. The invention is also directed to a method for treating learning and memory defects and neurological diseases associated with an abnormal auditory, visual, or somatosensory perception by inhibiting Nt5e or A1R expression or function in the brain.
Applicant(s) St. Jude Children'S Research Hospital, Inc
Representative Drug(s) D00BQR Drug Info N.A. Click to Show More [1]
2 D01ADE Drug Info N.A. [1]
3 D01NBW Drug Info N.A. [1]
4 D01OIQ Drug Info N.A. [1]
5 D02DLG Drug Info N.A. [1]
6 D03VLV Drug Info N.A. [1]
7 D03XTA Drug Info N.A. [1]
8 D04GYR Drug Info N.A. [1]
9 D06YAB Drug Info N.A. [1]
10 D07DGB Drug Info N.A. [1]
11 D09QNH Drug Info N.A. [1]
12 D09XUJ Drug Info N.A. [1]
13 D0AF4A Drug Info N.A. [1]
14 D0C2UP Drug Info N.A. [1]
15 D0C7ON Drug Info N.A. [1]
16 D0CH7Z Drug Info N.A. [1]
17 D0DF2M Drug Info N.A. [1]
18 D0FK2Q Drug Info N.A. [1]
19 D0H9IX Drug Info N.A. [1]
20 D0JF6W Drug Info N.A. [1]
21 D0LB7I Drug Info N.A. [1]
22 D0MA9U Drug Info N.A. [1]
23 D0QL7B Drug Info N.A. [1]
24 D0SK3R Drug Info N.A. [1]
25 D0U2YE Drug Info N.A. [1]
26 D0V5NK Drug Info N.A. [1]
27 D0V7OE Drug Info N.A. [1]
28 D0X1MK Drug Info N.A. [1]
29 D0Y2QO Drug Info N.A. [1]
30 D0Y9TP Drug Info N.A. [1]
Patent ID WO2015049447
Title 5'-Nucleotidase Inhibitors and Therapeutic Uses Thereof.
Abstract The subject matter of the present invention is compounds which have a 6-aminopurine backbone corresponding to formula (I): in which R1, R2, R3, X, Y and Z are as defined in any one of Claims 1 to 5, and Ar is a biphenyl or a naphthyl which may be substituted with R3, for use in the treatment of cancer.
Applicant(s) Centre National De La Recherche Scientifique
Representative Drug(s) D04TGG Drug Info N.A. Click to Show More [1]
2 D08LPX Drug Info N.A. [1]
3 D08ZDR Drug Info N.A. [1]
Patent ID WO2017120508
Title Modulators of 5'-Nucleotidase, Ecto and The Use Thereof.
Abstract Compounds that modulate the conversion of AMP to adenosine by 5'- nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5'-nucleotidase, ecto is also provided.
Applicant(s) Arcus Biosciences, Inc
Representative Drug(s) D0KS3G Drug Info N.A. [2]
Patent ID WO2015164573
Title Purine Derivatives As Cd73 Inhibitors for The Treatment of Cancer.
Abstract Provided are novel compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are inhibitors of CD73 and are useful in the treatment of cancer.
Applicant(s) Vitae Pharmaceuticals, Inc
Representative Drug(s) D0KS3G Drug Info N.A. [2]
United States Patent and Trademark Office (USPTO)
Patent ID US20160272643
Title 5-Nucleotidase Inhibitors and Therapeutic Uses Thereof.
Representative Drug(s) D04TGG Drug Info N.A. Click to Show More [1]
2 D08LPX Drug Info N.A. [1]
3 D08ZDR Drug Info N.A. [1]
References  Top
REF 1 Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
REF 2 Evaluation of WO2017098421: GSK's benzothiazine compounds as CD73 inhibitor filings.Expert Opin Ther Pat. 2018 Feb;28(2):167-171.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.